Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Host genetics contributes to the effectiveness of dendritic cell-based HIV immunotherapy

Full text
Author(s):
Reis, Edione C. [1] ; da Silva, Lais T. [2] ; da Silva, Wanessa C. [2] ; Rios, Alexandre [1] ; Duarte, Alberto J. [2] ; Oshiro, Telma M. [2] ; Crovella, Sergio [3] ; Pontillo, Alessandra [1]
Total Authors: 8
Affiliation:
[1] Univ Sao Paulo, ICB, Dept Imunol, Lab Imunogenet, Sao Paulo, SP - Brazil
[2] Univ Sao Paulo, Fac Med, Dept Dermatol, Lab Invest Med LIM 56, Sao Paulo, SP - Brazil
[3] Univ Fed Pernambuco, Dept Genet, Recife, PE - Brazil
Total Affiliations: 3
Document type: Journal article
Source: HUMAN VACCINES & IMMUNOTHERAPEUTICS; v. 14, n. 8, p. 1995-2002, 2018.
Web of Science Citations: 2
Abstract

Systems biological analysis has recently revealed how innate immune variants as well as gut microbiota impact the individual response to immunization. HIV-infected (HIV+) patients have a worse response rate after standard vaccinations, possibly due to the immune exhaustion, increased gut permeability and microbial translocation. In the last decade, dendritic cells (DC)-based immunotherapy has been proposed as an alternative approach to control HIV plasma viral load, however clinical trials showed a heterogeneity of immunization response. Hypothesizing that host genetics may importantly affects the outcome of immunotherapy in HIV+ patients, genetic polymorphisms' distribution and gene expression modulation were analyzed in a phase I/II clinical trial of DC-based immunotherapy according to immunization response, and quality of vaccine product (DC). Polymorphisms in genes previously associated with progression of HIV infection to AIDS (i.e.: PARD3B, CCL5) contribute to a better response to immunotherapy in HIV+ individuals, possibly through a systemic effect on host immune system, but also directly on vaccine product. Genes expression profile after immunization correlates with different degrees of immune chronic activation/exhaustion of HIV+ patients (i.e. PD1, IL7RA, EOMES), but also with anti-viral response and DC quality (i.e.: APOBEC3G, IL8, PPIA), suggested that an immunocompetent individual would have a better vaccine response. These findings showed once more that host genetics can affect the response to DC-based immunotherapy in HIV+ individuals, contributing to the heterogeneity of response observed in concluded trials; and it can be used as predictor of immunization success. (AU)

FAPESP's process: 17/22131-0 - Evaluation of aDC1 dendritic cells for anti-HIV immunotherapy
Grantee:Telma Miyuki Oshiro Sumida
Support Opportunities: Regular Research Grants
FAPESP's process: 15/23395-6 - Immunogenetics of the inflammasome and translational study "from bed to bench and back": analysis of variations in inflammasome genes in monogenic and multifactorial autoinflammatory diseases for differential diagnosis and therapeutic applications
Grantee:Alessandra Pontillo
Support Opportunities: Regular Research Grants
FAPESP's process: 13/06142-1 - Genomic signature of immune response against HIV-1 and its implications for dendritic cell-based therapeutic vaccine against HIV-1
Grantee:Alessandra Pontillo
Support Opportunities: Regular Research Grants